Anti-clotting drug Xarelto matches standard therapy in a Phase III trial

08/4/2010 | Bloomberg

Bayer's blood thinner Xarelto appeared to work as well as the standard-therapy combination of Sanofi-Aventis' Lovenox and warfarin in preventing deep vein thrombosis during a late-stage study. Patients who received Xarelto were as likely as those given the standard treatment to develop severe and uncontrolled bleeding.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care